Vigneron Nathalie, Abi Habib Joanna, Van den Eynde Benoit J
Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
Trends Cancer. 2017 Oct;3(10):726-741. doi: 10.1016/j.trecan.2017.07.007. Epub 2017 Aug 24.
Cancer immunotherapy has recently emerged as a forefront strategy to fight cancer. Key players in antitumor responses are CD8 cytolytic T lymphocytes (CTLs) that can detect tumor cells that carry antigens, in other words, small peptides bound to surface major histocompatibility complex (MHC) class I molecules. The success and safety of cancer immunotherapy strategies depends on the nature of the antigens recognized by the targeted T cells, their strict tumor specificity, and whether tumors and antigen-presenting cells can efficiently process the peptide. We review here the nature of the tumor antigens and their potential for the development of immunotherapeutic strategies. We also discuss the importance of proteasome in the production of these peptides in the context of immunotherapy and therapeutic cancer vaccines.
癌症免疫疗法最近已成为对抗癌症的前沿策略。抗肿瘤反应中的关键参与者是CD8细胞毒性T淋巴细胞（CTL），它可以检测携带抗原的肿瘤细胞，也就是说，与表面主要组织相容性复合体（MHC）I类分子结合的小肽。癌症免疫疗法策略的成功与安全性取决于靶向T细胞识别的抗原的性质、它们严格的肿瘤特异性，以及肿瘤和抗原呈递细胞是否能够有效地加工这些肽。我们在此综述肿瘤抗原的性质及其在免疫治疗策略开发中的潜力。我们还将讨论蛋白酶体在免疫治疗和治疗性癌症疫苗背景下这些肽产生过程中的重要性。
